Archive for the ‘Biotechnology’ Category

June was a hot month for investment in Israeli companies

Close to $850 million poured into Israeli firms in June 2017 to advance pharma, cybersecurity, e-commerce, autonomous-vehicle and other technologies. The month of June 2017 was hotter than usual in Israel, not only in terms of temperature but also in terms of investment. Here’s a roundup of activity over the past month.

Biolinerx In-Licenses Type 1 Diabetes Treatment With Israel Institutions

In an effort to develop and commercialize its antibody treatment for type 1 diabetes, BioLineRx has signed a worldwide, exclusive license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, B.G. Negev Technologies and Applications, and Hadasit Medical Research Services and Development, all based in Israel.

XTL Biopharmaceuticals Returns to NASDAQ

  XTL Biopharmaceuticals Ltd. (the « Company ») (tase:XTL), XTLBY -1.05% announced today that NASDAQ approved the Company’s listing application and its ADRs will be listed for trading on NASDAQ under the ticker symbol « XTLB ».

Massachusetts and Israel Continue to Support R&D Collaborations in the Life Sciences

TEL AVIV, Israel – June 11, 2013 – MATIMOP, the Israeli implementation agency, on behalf of the Office of the Chief Scientist (OCS) in the Ministry of Economy, and the Massachusetts Life Sciences Center (MLSC) today announced at the Biomed-IL conference in Tel Aviv the second round of grants awarded under the Massachusetts-Israel Innovation Partnership […]

Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel

Oramed to Present on Tuesday, June 11, 2013, at 3:10 p.m. (IDT) JERUSALEM, June 10, 2013 /PRNewswire via COMTEX/ — Oramed Pharmaceuticals Inc. (nasdaqcm:ORMP), a clinical-stage developer of oral delivery systems, announced today that it has been invited to present at the 12th National Life Science & Technology Week IATI-BioMed Conference taking place from June […]

Andromeda Announces the Results of an Extension to Its Phase III Study

YAVNE, Israel, June 5, 2013 (GLOBE NEWSWIRE) — Andromeda Biotech Ltd. announces the results from an Extension Study to its Phase III Clinical trial in type 1 diabetes patients treated with DiaPep277®.

President Obama’s Science Advisor to Speak at IATI-BioMed Israel 2013

TEL AVIV, Israel–(BUSINESS WIRE)–June 03, 2013– June 10-12, 2013, David Intercontinental Hotel, Tel Aviv, Israel — Dr. Eric Lander, the co-chair of U.S. President Barack Obama’s Council of Advisors on Science and Technology and a principal leader of the human genome project, will deliver a keynote address at the 12th annual IATI-BioMed Israel Conference 2013 […]

BrainStorm Receives 1.2 Million NIS Grant From Israel’s Office of the Chief Scientist

NEW YORK, NY and PETACH TIKVAH, ISRAEL–(Marketwired – Jun 4, 2013) – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company has received the third installment of the 2013 grant from Israel’s Office of the Chief Scientist (OCS) in the amount of approximately […]